GlassScriptPhysician profile
Seyed Mohammad Abedi
NPI 1033567409
$9,370.31
in general payments reported to CMS, 2019-2025
52 companies · $2,980 in 2025
The $2,980 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $657 · 2023: $3,630 · 2024: $2,104 · 2025: $2,980.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,549 · Consulting Fee: $2,310 · Education: $855.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,548.62 |
| Consulting Fee | $2,310.00 |
| Education | $854.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,176.01 | 2022-2025 | Imfinzi, Enhertu, Calquence |
| Incyte Corporation | $887.41 | 2022-2025 | Monjuvi, Zynyz, Jakafi |
| E.R. Squibb & Sons, L.L.C. | $537.59 | 2023-2025 | Opdivo, Augtyro, Opdualag |
| Lilly USA, LLC | $446.41 | 2023-2025 | Jaypirca, Verzenio, Retevmo |
| Novartis Pharmaceuticals Corporation | $433.34 | 2022-2025 | |
| Astellas Pharma US INC | $355.31 | 2022-2025 | Padcev, Xospata, Vyloy |
| Pfizer INC. | $351.19 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $324.72 | 2023-2025 | Libtayo |
| Janssen Biotech, INC. | $324.11 | 2022-2025 | Tecvayli, Darzalex, Talvey |
| Seagen INC. | $280.15 | 2022-2025 | Padcev, Adcetris |
| Celgene Corporation | $246.16 | 2022-2025 | Reblozyl, Opdivo |
| Abbvie INC. | $225.05 | 2022-2025 | |
| Glaxosmithkline, LLC. | $219.54 | 2023-2025 | Ojjaara, Jemperli |
| Aveo Pharmaceuticals, INC. | $184.57 | 2022-2025 | Fotivda |
| Amgen INC. | $178.95 | 2022-2023 | Nplate, Vectibix, Lumakras |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tempus Ai, INC | $175.34 | 2024 | |
| Eisai INC. | $171.50 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $161.78 | 2022-2024 | Iclusig, Vonvendi, Fruzaqla |
| Jazz Pharmaceuticals INC. | $137.73 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $129.23 | 2023-2025 | Ultomiris |
| Genentech USA, INC. | $105.48 | 2023-2025 | Tecentriq, Polivy, Alecensa |
| Karyopharm Therapeutics INC. | $101.24 | 2023-2025 | Xpovio |
| Genzyme Corporation | $93.79 | 2023-2024 | |
| Stemline Therapeutics INC. | $85.03 | 2023-2025 | Orserdu |
| Sobi, INC | $83.26 | 2023-2025 | |
| Gilead Sciences, INC. | $68.73 | 2023-2025 | Trodelvy |
| Genmab U.S., INC. | $63.86 | 2023-2025 | Epkinly |
| Bayer Healthcare Pharmaceuticals INC. | $58.48 | 2023-2025 | |
| Ipsen Biopharmaceuticals, INC | $56.87 | 2023-2025 | Onivyde, Somatuline Depot |
| Beigene USA, INC. | $50.85 | 2024 | Brukinsa |
| Taiho Oncology, INC. | $47.15 | 2023-2024 | |
| Deciphera Pharmaceuticals INC. | $46.22 | 2024-2025 | Qinlock, Romvimza |
| Secura Bio, INC. | $43.77 | 2024 | Copiktra |
| Puma Biotechnology, INC. | $43.05 | 2025 | |
| Cti Biopharma Corp. | $42.95 | 2023 | Vonjo |
| Array Biopharma INC | $40.23 | 2022-2025 | Braftovi |
| Adaptive Biotechnologies Corporation | $40.22 | 2024 | Clonoseq |
| Rigel Pharmaceuticals, INC. | $39.36 | 2024 | Rezlidhia, Tavalisse |
| Agios Pharmaceuticals, INC. | $36.23 | 2024-2025 | Pyrukynd |
| Merck Sharp & Dohme LLC | $31.33 | 2024 | Keytruda |
| Pharmacyclics LLC, An Abbvie Company | $29.04 | 2023 | Imbruvica |
| Pharmaessentia USA Corporation | $26.17 | 2025 | Besremi |
| Beone Medicines USA, INC. | $24.61 | 2025 | Brukinsa |
| Blueprint Medicines Corporation | $23.16 | 2023 | Ayvakit |
| Tersera Therapeutics LLC | $20.55 | 2023 | Zoladex |
| Adc Therapeutics America, INC. | $20.30 | 2025 | |
| Tolmar, INC. | $20.12 | 2024 | |
| Daiichi Sankyo INC. | $18.18 | 2025 | Datroway |
| Springworks Therapeutics, INC. | $17.93 | 2025 | Ogsiveo |
| Octapharma USA, INC. | $16.67 | 2023 | Panzyga |
| Morphosys, US INC. | $16.55 | 2023 | Monjuvi |
| Tactile Systems Technology INC | $12.84 | 2023 | Entre Plus, Flexitouch Plus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seyed Abedi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.